DDInter255 DDInter462
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Busulfan {u} (Compound) upregulates {v} (Gene) DUSP11
DUSP11 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Busulfan {u} (Compound) downregulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Busulfan {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Busulfan {u} (Compound) upregulates {v} (Gene) TEX10
TEX10 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Busulfan {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Busulfan {u} (Compound) upregulates {v} (Gene) DUSP11
DUSP11 {u} (Gene) regulates {v} (Gene) SESN1
SESN1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Busulfan {u} (Compound) upregulates {v} (Gene) PTPRC
PTPRC {u} (Gene) is regulated by {v} (Gene) AGL
AGL {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Busulfan {u} (Compound) downregulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Busulfan (Compound) upregulates DUSP11 (Gene) and DUSP11 (Gene) is upregulated by Dabrafenib (Compound)
Busulfan (Compound) downregulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Busulfan (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Dabrafenib (Compound)
Busulfan (Compound) upregulates TEX10 (Gene) and TEX10 (Gene) is downregulated by Dabrafenib (Compound)
Busulfan (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Busulfan (Compound) upregulates DUSP11 (Gene) and DUSP11 (Gene) regulates SESN1 (Gene) and SESN1 (Gene) is upregulated by Dabrafenib (Compound)
Busulfan (Compound) upregulates PTPRC (Gene) and PTPRC (Gene) is regulated by AGL (Gene) and AGL (Gene) is upregulated by Dabrafenib (Compound)
Busulfan (Compound) downregulates ERBB2 (Gene) and ERBB2 (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)